Hydrous fluid composition

Abstract

To provide a hydrous fluid composition capable of maintaining anti-norovirus activity even when a lysozyme modified material is stored in water or in a low concentration polar organic solvent.SOLUTION: A hydrous fluid composition contains a lysozyme modified product and / or a salt thereof, and a cationic surfactant, the hydrous fluid composition having a fluorescence intensity, as defined in (A) below, of 5000 or more. (A) Fluorescence intensity: obtained by diluting with a phosphate buffer (pH 7.0) so that the concentration of the lysozyme modified product and / or the salt is 0.05% by mass in terms of solid content and the concentration of lysozyme modified product and / or the salt and the concentration of a phosphate is 0.2 M. The liquid obtained by adding 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid to 5 mL of the diluted solution was allowed to react at room temperature for 30 minutes, and the excitation wavelength was 390 nm (excitation bandwidth 10 nm) and the fluorescence intensity measured under the condition of excitation wavelength 390 nm (excitation bandwidth 10 nm) and fluorescence wavelength 470 nm (fluorescence bandwidth 10 nm).SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a water-containing fluid composition. [Background technology]

[0002] Lysozyme is an enzyme that is widely present in the biological world, including eggs, animal tissues, body fluids, and plants. Industrially, lysozyme isolated from egg white is used in food and pharmaceutical products (Patent Document 1). For example, lysozyme is widely used as a component of disinfectants because of its antibacterial properties.

[0003] The inventors previously discovered that a denatured lysozyme obtained by denaturing lysozyme under specific conditions has anti-norovirus activity, and that storing the denatured lysozyme in the presence of a high concentration of a polar organic solvent can suppress the decline in the anti-norovirus activity (Patent Document 1). However, there was a problem that when denatured lysozyme was stored in water or a low concentration of a polar organic solvent, its anti-norovirus activity decreased during storage. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2016 / 017784 Summary of the Invention [Problem to be solved by the invention]

[0005] Therefore, an object of the present invention is to provide a water-containing fluid composition which can maintain anti-norovirus activity even when a denatured lysozyme is stored in water or a low-concentration polar organic solvent. [Means for solving the problem]

[0006] As a result of intensive research to solve the above-mentioned problems, the inventors discovered that by combining a denatured lysozyme with a cationic surfactant, the anti-norovirus activity can be maintained even when the denatured lysozyme is stored in water or a low concentration of a polar organic solvent, and thus completed the present invention.

[0007] The present invention will be described in detail below. In the present invention, unless otherwise specified, "parts" means "parts by mass", "%" means "% by mass", and "% RH" means relative humidity.

[0008] That is, the present invention provides (1) An aqueous fluid composition comprising a denatured lysozyme and / or a salt thereof, a preservative, and a cationic surfactant, the aqueous fluid composition having a fluorescence intensity of 5000 or more as defined in the following (A): (A) Fluorescence intensity: the aqueous fluid composition is diluted with a phosphate buffer (pH 7.0) so that the concentration of the denatured lysozyme and / or its salt is 0.05% by mass in terms of solid content and the concentration of the phosphate is 0.2 M. 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid is added to 5 mL of the diluted solution, and the solution is reacted at room temperature for 30 minutes. The fluorescence intensity of the solution is measured under the conditions of an excitation wavelength of 390 nm (excitation bandwidth of 10 nm) and a fluorescence wavelength of 470 nm (fluorescence bandwidth of 10 nm). In the water-containing fluid composition of (2)(1), The content ratio of the cationic surfactant to 1 part of the denatured lysozyme and / or its salt is 0.005 parts or more and 0.1 parts or less. water-containing fluid composition, (3) A method for inactivating bacteria and / or viruses, comprising a step of contacting an object with the aqueous fluid composition according to (1) or (2). water-containing fluid composition, It is. Effect of the Invention

[0009] The above-mentioned water-containing fluid composition can be used, for example, for cleaning pharmaceuticals, quasi-drugs, cosmetics, and food, or for sanitary purposes. In this case, the above-mentioned water-containing fluid composition can be used for removing norovirus. More specifically, the above-mentioned water-containing fluid composition can be used, for example, in a form contained in a container (for example, a container equipped with a nozzle or spray, or a container not equipped with these) or in a form impregnated into a nonwoven fabric. The water-containing fluid composition may be used as a raw material or a product in process for the above-mentioned medicines, quasi-drugs, cosmetics, food cleaning applications, or sanitary applications. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] <Water-containing fluid composition> An aqueous fluid composition according to one embodiment of the present invention is an aqueous fluid composition comprising a denatured lysozyme and / or a salt thereof and a cationic surfactant, and the aqueous fluid composition has a fluorescence intensity, as defined in (A) below, of 5000 or more. (A) Fluorescence intensity: the aqueous fluid composition is diluted with a phosphate buffer (pH 7.0) so that the concentration of the denatured lysozyme and / or its salt is 0.05% by mass in terms of solid content and the concentration of the phosphate is 0.2 M. 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid is added to 5 mL of the diluted solution, and the solution is reacted at room temperature for 30 minutes. The fluorescence intensity of the solution is measured under the conditions of an excitation wavelength of 390 nm (excitation bandwidth of 10 nm) and a fluorescence wavelength of 470 nm (fluorescence bandwidth of 10 nm).

[0011] The water-containing fluid composition in the present invention is a composition that contains water and has a viscosity (e.g., 1 to 100,000 mPa s) that allows it to be deformed, and is a concept that includes liquid compositions with a low viscosity that allows it to be sprayed, and gel-like compositions. The solvent is not particularly limited as long as it can dissolve or disperse the lysozyme denatured product and / or its salt uniformly, and for example, water or alcohol can be used. In addition, in the present invention, "room temperature" refers to a temperature between 20°C and 25°C.

[0012] The fluorescence intensity of the water-containing fluid composition of the present invention and the denatured lysozyme and / or its salt described below is a value measured by the method described in Canadian Institute of Food Science and Technology, Vol. 18, No. 4, pp. 290-295, 1985. The phosphate buffer used in measuring the fluorescence intensity of the denatured lysozyme and / or its salt in the present invention is prepared with sodium dihydrogen phosphate and disodium hydrogen phosphate. The fluorescence intensity of the denatured lysozyme and / or its salt in the present invention is a value obtained by subtracting the fluorescence intensity of 0.2 M phosphate buffer (pH 7.0, containing sodium dihydrogen phosphate and disodium hydrogen phosphate as phosphates) separately measured as a blank value. The fluorescence intensity of the aqueous fluid composition according to the present embodiment and the denatured lysozyme and / or its salt according to the embodiment described later is a value measured using a FP-8500 fluorescence spectrophotometer manufactured by JASCO Corporation under the following conditions: excitation wavelength 390 nm, excitation bandwidth 10 nm, fluorescence wavelength 470 nm, fluorescence bandwidth 10 nm, response 0.5 sec, sensitivity Low (about 270±10 V) (power supply frequency (50 / 60 Hz)), and peristaltic shipper SHP-820 type. Note that the measurement can also be performed using other fluorescence spectrophotometers, but in that case, the measurement conditions such as sensitivity must be adjusted to those specified in the present application.

[0013] <Denatured lysozyme and / or its salt> In the present invention, the term "lysozyme" refers to a protein having the ability to hydrolyze the β-1,4 bond between N-acetylglucosamine and N-acetylmuramic acid. Lysozymes are found widely in the living world, including eggs, animal tissues, body fluids, and plants, and are broadly classified into the following five families based on their substrate specificity and structure. 1. Lysozyme (bacterial type) 2. Lysozyme (chicken type) 3. Lysozyme (goose type) 4. Lysozyme (phage type; V type) 5. Lysozyme (CH type) In the aqueous fluid composition according to the present embodiment, any of the above five families can be used as the raw material for the lysozyme denaturation product and / or salt thereof. Among these lysozymes, lysozymes (chicken type) such as egg white lysozyme and human lysozyme are preferred as the raw material lysozyme. In the aqueous fluid composition according to the present embodiment, it is more preferred that the raw material lysozyme for the lysozyme denaturation product and / or salt thereof is derived from egg white lysozyme, in that it has a better inactivating effect on norovirus, is low cost and is easily available. In the present invention, the term "denatured lysozyme" refers to a denatured lysozyme that has a three-dimensional structure different from that of lysozyme and / or a salt thereof. Methods for denaturing lysozyme and / or its salts include heat treatment, acid treatment, alkali treatment, enzyme treatment, organic solvent treatment, surfactant treatment, oxidation treatment, reduction treatment, high pressure treatment, etc. These denaturing treatments can be performed alone or in combination. The denatured lysozyme also includes lysozyme-derived peptides obtained by decomposing lysozyme and / or its salts. Among these, lysozyme and / or its salts that have been heat-denatured (hereinafter simply referred to as "heat-denatured products") are preferred, since denatured lysozyme and / or its salts that have anti-norovirus activity can be obtained relatively inexpensively. Examples of salts of denatured lysozyme include food additives or pharma- ceutically acceptable salts, such as salts of inorganic acids, such as hydrochloric acid, carbonic acid, phosphoric acid, boric acid, hexametaphosphoric acid, nitric acid, and sulfuric acid, and salts of organic acids, such as citric acid, tartaric acid, succinic acid, malic acid, acetic acid, glutamic acid, glycerophosphoric acid, and gluconic acid. Among the salts of lysozyme, salts of inorganic acids are preferred, and hydrochloride is more preferred because it is widely used as an anti-inflammatory agent and its safety has been established. The aqueous fluid composition according to the present embodiment may contain at least one selected from a lysozyme denaturant and / or a salt thereof. When the aqueous fluid composition according to the present embodiment contains a plurality of types of lysozyme denaturant and / or a salt thereof, the concentration of the lysozyme denaturant and / or a salt thereof (in terms of solid content) means the concentration of the total amount of the lysozyme denaturant and / or a salt thereof (in terms of solid content).

[0014] <Method for heat denaturation of lysozyme and / or its salt> The heating conditions for heat denaturation are not particularly limited as long as the denaturation of lysozyme and / or its salt is adequate; however, it is preferable to heat lysozyme and / or its salt at a temperature of 50°C or higher and 130°C or lower, and more preferably at a temperature of 60°C or higher or 70°C or higher. The thermal denaturation method may involve dissolving lysozyme and / or a salt thereof in a solvent and heating it, or heating it as a powder. When dissolving lysozyme and / or a salt thereof and heating it, the heating time can be determined according to the lysozyme heating temperature, and may be 1 minute or more and 720 minutes or less. When heating it as a powder, the heating time is preferably 1 day or more and less than 30 days. The solvent is not limited as long as it can dissolve lysozyme and / or a salt thereof, and may be, for example, water or an organic solvent containing water.

[0015] <Concentration of denatured lysozyme and / or its salt> In the aqueous fluid composition of this embodiment, in order to more reliably suppress a decrease in anti-norovirus activity, the concentration of the denatured lysozyme and / or its salt relative to the total amount of the aqueous fluid composition is preferably 0.1% or more and 10% or less, in terms of solids, and further preferably 0.2% or more, 0.5% or more, 0.6% or more, 0.7% or more, and also preferably 5% or less, and further preferably 4% or less, and particularly preferably 2% or less.

[0016] <Cationic surfactant> The water-containing fluid composition according to this embodiment contains a cationic surfactant. The aqueous fluid composition of this embodiment combines a denatured lysozyme with a cationic surfactant, so that the anti-norovirus activity can be maintained even when the denatured lysozyme is stored in water or low-concentration alcohol. A cationic surfactant is a surfactant having a cationic hydrophilic group, and examples of such surfactants include amine salt types, such as alkylamine salts, amide-bonded amine salts, and ester-bonded amine salts; ammonium salt types, such as alkylammonium salts, amide-bonded ammonium salts, ester-bonded ammonium salts, and ether-bonded ammonium salts; and pyridinium salt types, such as alkylpyridinium salts, amide-bonded pyridinium salts, ether-bonded pyridinium salts, and ester-bonded pyridinium salts; and the ammonium salt types are particularly preferred because they are more likely to provide the effects of the present invention. Furthermore, among the ammonium salt types, quaternary ammonium salt types are preferable, and among these, cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, and lauryltrimethylammonium chloride are preferable, and cetyltrimethylammonium chloride is particularly preferable.

[0017] <Concentration of cationic surfactant> In the aqueous fluid composition of this embodiment, in order to more reliably suppress a decrease in the anti-norovirus activity of the lysozyme denatured product, the concentration of the cationic surfactant is preferably 0.01% or more and 10% or less, more preferably 0.015% or more, particularly preferably 0.02% or more, and is preferably 5% or less, more preferably 1% or less, particularly preferably 0.5% or less.

[0018] <Ratio of denatured lysozyme and cationic surfactant> In the aqueous fluid composition according to the present embodiment, the cationic surfactant is preferably contained in an amount of 0.005 parts or more, more preferably 0.01 parts or more, or even 0.02 parts or more per part of the lysozyme denatured product in order to suppress a decrease in the anti-norovirus activity of the lysozyme denatured product. In addition, the amount of the cationic surfactant per part of the lysozyme denatured product is 0.1 parts or less, or even 0.05 parts or less, in order to obtain a sufficient effect.

[0019] <Polar organic solvent> The water-containing fluid composition according to the present embodiment may contain a polar organic solvent. In the present invention, the term "polar organic solvent" refers to an organic solvent having affinity for water, more specifically, an organic solvent miscible with water. Examples of polar organic solvents include monohydric alcohols having 1 to 4 carbon atoms (preferably 3 or less), such as ethanol, methanol, 1-propanol, 2-propanol, and n-butanol; water-soluble alcohols (alcohol-based solvents) including polyhydric alcohols, such as polyhydric alcohols, such as glycerin, ethylene glycol, diethylene glycol, propylene glycol, polyethylene glycol, butylene glycol, dipropylene glycol, and sorbitol; ketone-based solvents, such as acetone and methyl ethyl ketone; dioxane, tetrahydrofuran, acetonitrile, and N-methylpyrrolidone; and one of these can be used alone or in combination of two or more. Among these, the polar organic solvent preferably contains an alcohol-based solvent, and more preferably contains ethanol, in terms of less burden on the living body. In the aqueous fluid composition of this embodiment, in order to provide excellent solubility for denatured lysozyme and / or its salt and to effectively suppress a decrease in anti-norovirus activity even when the water content is high, the concentration of the polar organic solvent in the aqueous fluid composition of this embodiment is preferably 0% or more and less than 55%, based on the total amount of the aqueous fluid composition, more preferably 30% or less, 10% or less, and further preferably contains substantially no polar organic solvent. Here, "substantially free of polar organic solvent" means that the polar organic solvent content is 1% or less, based on the total amount of the water-containing fluid composition, and more preferably the polar organic solvent content is 0.5% by mass or less, and particularly preferably 0.0% by mass.

[0020] <Anti-norovirus activity retention rate> The anti-norovirus activity retention rate in the present invention is indicated by the value of the anti-norovirus activity of the aqueous fluid composition of the present invention 4 weeks after preparation of the composition relative to the value of the anti-norovirus activity immediately after preparation of the aqueous fluid composition. The retention rate of anti-norovirus activity of the aqueous fluid composition of the present invention is preferably 50% or more, more preferably 60% or more, and even more preferably 70% or more.

[0021] <Other materials> The water-containing fluid composition according to this embodiment may contain other ingredients in addition to the denatured lysozyme, the polar organic solvent, and water. Other materials that can be used in appropriate combination include bacteriostatic agents such as glycine, organic acids, sodium benzoate, sodium sorbate, sodium propionate, sodium dehydrogenase, paraoxybenzoic acid esters, sodium sulfite, EDTA, chlorhexidine gluconate, alkyldiaminoethylglycine chloride, iodine tincture, povidone iodine, cetyl benzalkonium oxide, triclosan, chloroxylenol, isopropylmethylphenol, ε-polylysine, lactoferrin, nisin, bacteriocin, Aralia udo extract, Styrax japonica extract, Artemisia capillaris extract, enzymatically hydrolyzed Job's tears extract, Shirako protein extract, thujaplicin, and pectin hydrolysates. The water-containing fluid composition according to this embodiment may further contain additives as necessary, such as pH adjusters, such as citric acid, sodium citrate, sodium hydroxide, and triethanolamine; antioxidants, such as tocopherol acetate; and thickeners, such as carboxyvinyl polymers and hydroxyethyl cellulose.

[0022] <Dosage form> The viscosity of the water-containing fluid composition according to this embodiment can be appropriately determined depending on the method of use. For example, by preparing a liquid formulation with a sprayable viscosity and filling it into a container such as a trigger sprayer, a pump container, a squeeze container, or an aerosol container, droplets containing the water-containing fluid composition according to this embodiment can be sprayed onto fingers, food, cooking utensils, the living environment, vomit, excrement, etc., thereby easily inactivating viruses. That is, the container contains the water-containing fluid composition according to this embodiment. Furthermore, viruses can be easily inactivated by immersing the object to be inactivated (e.g., hands, food, medical equipment, medical instruments, cooking utensils, living environment) in the aqueous fluid composition according to this embodiment. The water-containing fluid composition according to the present embodiment can be used in the form of a sheet in which a nonwoven fabric is impregnated with the water-containing fluid composition according to the present embodiment. That is, the nonwoven fabric is impregnated with the water-containing fluid composition according to the present embodiment. In this case, the material of the nonwoven fabric can be, for example, paper or fiber. By contacting the sheet in which the nonwoven fabric is impregnated with the water-containing fluid composition according to the present embodiment with the surface of the target object, the virus can be easily inactivated. Furthermore, by preparing the water-containing fluid composition according to this embodiment into a lotion, it can be used as a cosmetic product or an external preparation for skin, such as a drug or quasi-drug. The water-containing fluid composition according to this embodiment may be used as a raw material or a work-in-progress for the above-mentioned medicines, quasi-drugs, cosmetics, and food cleaning applications, or for sanitary purposes. EXAMPLES

[0023] The present invention will be specifically described below with reference to examples and comparative examples. However, the present invention should not be construed as being limited to the contents of the following examples and comparative examples.

[0024] [Example 1] Egg white lysozyme (product name: "Lyzosyme Powder P5", manufactured by Bouwhuis Enthoven) was dissolved in distilled water to a lysozyme content of 1%, and the solution was heated at 90°C for 60 minutes and then cooled in air. To this solution, the preservative methylparaben and the cationic surfactant cetyltrimethylammonium chloride were added to a content of 0.05% and 0.0075%, respectively, to obtain a water-containing fluid composition of the present invention.

[0025] In Examples 2 to 10, the water-containing fluid compositions of the present invention were obtained in the same manner as in Example 1, except that the contents of each component and the cationic surfactant were changed as shown in Table 1.

[0026] [Comparative Example 1] An aqueous solution containing a denatured lysozyme and / or a salt thereof, and methylparaben as a preservative was obtained in the same manner as in Example 1, except that no cationic surfactant was used.

[0027] [Comparative Example 2] An aqueous solution containing a lysozyme-modified product and / or its salt, and the preservative methylparaben was obtained in the same manner as in Comparative Example 1, except that the content of the lysozyme-modified product was 4% and the content of methylparaben was 0.2%.

[0028] [Test Example 1] Fluorescence Intensity of Water-Containing Fluid Composition The fluorescence intensities of the water-containing fluid compositions of Examples 1 to 10 and Comparative Examples 1 and 2 were measured using an absorptiometer (model name "UV-2450", manufactured by Shimadzu Corporation) under the conditions described below. Specifically, 5 mL of the diluted solution was diluted with phosphate buffer (pH 7.0) so that the concentration of the denatured lysozyme and / or its salt was 0.05% in terms of solid content and the concentration of the phosphate was 0.2 M. 25 μL of an 8 mM methanol solution of 1,8-anilinonaphthalenesulfonic acid was added to the diluted solution, and the resulting solution was reacted at room temperature for 30 minutes. The fluorescence intensity of the solution was measured under conditions of an excitation wavelength of 390 nm (excitation bandwidth 10 nm) and a fluorescence wavelength of 470 nm (fluorescence bandwidth 10 nm). The aqueous fluid compositions of Examples 1 to 10 and the aqueous solutions of Comparative Examples 1 and 2 all had a fluorescence intensity of 5,000 or more.

[0029] [Test Example 2] Measurement of anti-norovirus activity of water-containing fluid composition The anti-norovirus activity of the aqueous fluid compositions of Examples 1 to 10 and Comparative Examples 1 and 2 was measured and evaluated by a plaque assay method. The specific method is as described below. The anti-norovirus activity is a value measured for the aqueous fluid compositions of Examples 1 to 10 and Comparative Examples 1 and 2, in which the concentration (converted into solid content) of the denatured lysozyme and / or its salt is the value shown in Table 1.

[0030] <Macrophage cell culture> Mouse macrophage cell line (RAW264.7 cells) was cultured in a 6-well plate until it reached 60-80% confluence.

[0031] <Preparation of norovirus fluid> Norovirus infectivity (PFU / mL) is 10 6 ~10 7 A norovirus solution with approximately PFU / mL was prepared as follows. First, mouse macrophage cell line (RAW264.7 cells) was cultured until confluent, and 1 mL of norovirus stock solution was inoculated into the confluent cells and cultured for 2 days at 37°C and 5% CO2. Murine norovirus strain 1 (MNV-1) (Effect of Food Residues on Norovirus Survival on Stainless Steel Surfaces) was used as the norovirus stock solution. The MNV-1 used was provided by Dr. Herbert W. Virgin of Washington University. After the incubation, the cells were visually confirmed to have detached, and the cells were disrupted by freezing and thawing four times to release the virus from the cells. Then, the cells were dispensed into 50 mL centrifuge tubes and centrifuged (8000 g, 10 min) to obtain an infectious titer (PFU / mL) of 10 6 ~10 7 A norovirus solution was obtained with a concentration of about PFU / mL. This norovirus solution was stored at -80°C and thawed prior to use.

[0032] <Preparation of a mixture of aqueous fluid composition and norovirus> For Examples 1 to 10 and Comparative Examples 1 and 2, 1 part of the norovirus liquid was added to 1 part by mass of the solution immediately after preparation and 1 part by mass of the solution 4 weeks after preparation, and then the mixture was left at room temperature for 1 minute to obtain a mixture of the aqueous fluid composition and norovirus of Examples 1 to 10 and Comparative Examples 1 and 2 (hereinafter referred to as norovirus mixture).

[0033] <Measurement of infectivity titer> The infectivity titers of the norovirus liquid and the norovirus mixed liquid, and the infectivity titer of the mixed liquid after being left to stand for 1 minute, were calculated by the following method. Specifically, the norovirus liquid or the norovirus mixture is x The diluted sample was diluted 1:1, where x is an integer of 2 or more, and the dilution rate was adjusted so that the number of plaques was about 10 to 100. After leaving the plate in place for 60 seconds, the diluted sample was inoculated into two wells at 500 μL / well, and then incubated at room temperature for 1 hour while shaking to prevent the mouse macrophage cell line (RAW264.7 cells) from drying out, allowing the mouse macrophage cell line to be infected with norovirus. The entire inoculum (500 μL / well) on the 6-well plate was removed, and 2 ml / well of 1.5% Sea Plaque Agarose-DMEM (37°C) was overlaid. After solidification, the plate was cultured at 37°C and 5% CO2 for 2 days. After 2 days of incubation, 0.03% neutral red solution, which was a staining solution, was layered on the plate at 2 mL / well, and incubated at 37°C and 5% CO2 for 1 hour. After incubation, the entire amount of 0.03% neutral red solution was removed, and the number of plaques was visually counted. From the number of plaques obtained and the dilution ratio, the infectivity titer (PFU / mL) of the norovirus mixture (or norovirus liquid) after leaving for 1 minute was calculated. The infectivity titer of the norovirus mixture before leaving for 1 minute was calculated by multiplying the infectivity titer of the norovirus liquid by the mixing ratio (1 / 2) of the norovirus liquid and the aqueous fluid composition in the norovirus mixture.

[0034] The anti-norovirus activity of the control norovirus liquid, and the aqueous fluid compositions of Examples 1 to 10 and Comparative Examples 1 and 2 was calculated using the following formula (1), and the retention rate of anti-norovirus activity 4 weeks after preparation was confirmed, with the retention rate immediately after preparation being the base value. The anti-norovirus activity retention rates of the control, and the aqueous fluid compositions of Examples 1 to 10 and Comparative Examples 1 and 2 are as shown in Table 1. Anti-norovirus activity = Log 10(Infectivity of norovirus mixture before leaving it for 1 minute)-Log 10 (Infectivity of norovirus mixture after standing for 1 minute) Equation (1)

[0035] [Table 1]

[0036] As shown in Table 1, the aqueous fluid compositions of the present invention containing a cationic surfactant (Examples 1 to 10) had an anti-norovirus activity retention rate of 50% or more 4 weeks after preparation, despite the inclusion of a preservative. In particular, the examples in which cetyltrimethylammonium chloride was used as the cationic surfactant (Examples 1 to 3, 7) or the examples in which the content of the cationic surfactant per part of denatured lysozyme and / or its salt was 0.02 part or more (Examples 2 to 6, 7, 9, 10) had an anti-norovirus activity retention rate of 70%, demonstrating particularly excellent effects in maintaining anti-norovirus activity. On the other hand, in the aqueous solutions not containing a cationic surfactant (Comparative Examples 1 and 2), the retention rate of anti-norovirus activity 4 weeks after preparation was lower than that of the control, indicating that the anti-norovirus activity could not be maintained. These results demonstrate that cationic surfactants contribute to maintaining the anti-norovirus activity of denatured lysozyme and / or its salts even when they contain a preservative.

[0037] [Examples 11 to 14] The aqueous fluid composition of the present invention was obtained in the same manner as in Example 1, except that the contents of the denatured lysozyme and / or its salt, the preservative phenoxyethanol, and the cationic surfactant, and the type of cationic surfactant were changed as shown in Table 2.

[0038] [Comparative Example 3] An aqueous solution containing a denatured lysozyme and / or a salt thereof, and phenoxyethanol as a preservative was obtained in the same manner as in Example 1, except that no cationic surfactant was used.

[0039] The water-containing fluid compositions of Examples 11 to 14 and the aqueous solution of Comparative Example 2 were subjected to the measurements of Test Example 1 and Test Example 2. In Test Example 1, the aqueous solutions of Examples 11 to 14 and Comparative Example 3 all had a fluorescence intensity of 5,000 or more. The retention rate of anti-norovirus activity measured in Test Example 2 is shown in Table 2.

[0040] [Table 2] TIFF2025025637000002.tif59160

[0041] Examples 11 to 14, in which the preservative was changed to phenoxyethanol, also showed a similar tendency to Examples 1 to 10, with the anti-norovirus activity retention rate being 50% or more 4 weeks after preparation.

Claims

1. a denatured lysozyme and / or a salt thereof, a preservative, and a cationic surfactant; A water-containing fluid composition comprising: The aqueous fluid composition has a fluorescence intensity of 5000 or more as defined in the following (A): Water-containing fluid composition. (A) Fluorescence intensity: the aqueous fluid composition is diluted with a phosphate buffer (pH 7.0) so that the concentration of the denatured lysozyme and / or its salt is 0.05% by mass in terms of solid content and the concentration of the phosphate is 0.2 M. 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid is added to 5 mL of the diluted solution, and the solution is reacted at room temperature for 30 minutes. The fluorescence intensity of the solution is measured under the conditions of an excitation wavelength of 390 nm (excitation bandwidth 10 nm) and a fluorescence wavelength of 470 nm (fluorescence bandwidth 10 nm).

2. The water-containing fluid composition according to claim 1, The content ratio of the cationic surfactant to 1 part of the denatured lysozyme and / or its salt is 0.005 parts or more and 0.1 parts or less. Water-containing fluid composition.

3. A method for inactivating bacteria and / or viruses, comprising a step of contacting an object with the aqueous fluid composition according to claim 1 or 2.

Images